Tobramycin overdosage: Difference between revisions
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Tobramycin}} {{CMG}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TOBI (TOBRAMYCIN) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATI...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Overdosage== | |||
Signs and symptoms of acute toxicity from overdosage of IV tobramycin might include [[dizziness]], [[tinnitus]], [[vertigo]], loss of high-tone hearing acuity, [[respiratory failure]], neuromuscular blockade, and renal impairment. Administration by inhalation results in low systemic bioavailability of tobramycin. Tobramycin is not significantly absorbed following oral administration. Tobramycin serum concentrations may be helpful in monitoring overdosage. | |||
In all cases of suspected overdosage, physicians should contact the Regional Poison Control Center for information about effective treatment. In the case of any overdosage, the possibility of drug interactions with alterations in drug disposition should be considered.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TOBI (TOBRAMYCIN) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94f9e516-6bf6-4e30-8dde-8833c25c2560 | publisher = | date = | accessdate = }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TOBI (TOBRAMYCIN) SOLUTION [NOVARTIS PHARMACEUTICALS CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94f9e516-6bf6-4e30-8dde-8833c25c2560 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== |
Latest revision as of 20:12, 6 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overdosage
Signs and symptoms of acute toxicity from overdosage of IV tobramycin might include dizziness, tinnitus, vertigo, loss of high-tone hearing acuity, respiratory failure, neuromuscular blockade, and renal impairment. Administration by inhalation results in low systemic bioavailability of tobramycin. Tobramycin is not significantly absorbed following oral administration. Tobramycin serum concentrations may be helpful in monitoring overdosage.
In all cases of suspected overdosage, physicians should contact the Regional Poison Control Center for information about effective treatment. In the case of any overdosage, the possibility of drug interactions with alterations in drug disposition should be considered.[1]
References
Adapted from the FDA Package Insert.